oalib

OALib Journal期刊

ISSN: 2333-9721

费用：99美元

投稿

时间不限

( 2026 )

( 2025 )

( 2024 )

( 2023 )

自定义范围…

匹配条件： “small cell carcinoma of lung.” ，找到相关结果约1000条。
列表显示的所有文章，均可免费获取
第1页/共1000条
每页显示 条
Clinicopathological Profile of Lung Cancers at an Institute from South India—A Record Based Retrospective Cohort Study  [PDF]
Vinod Ramani, Choudhury Bijit, Sarathy Vinu, Jayappa Srinivas Belagutti, Naik Radheshyam
Advances in Lung Cancer (ALC) , 2020, DOI: 10.4236/alc.2020.93005
Abstract: Introduction: Apart from smoking as the known risk factor for lung cancer, recent developments implicate occupational exposure to carcinogens, indoor air pollution and dietary factors as other causative agents. In our study, we have analyzed the clinical and pathological profile of lung cancer patients treated at our center over a period of 8 years. Aim: To find the demographic and clinicopathological profile of lung cancer patients admitted to the oncology unit. Methods: This retrospective record based analysis includes a cohort of 1248 patients diagnosed with lung cancer, at a tertiary cancer care center in Bangalore, South India. This study includes data of patients admitted during the period 2010 to 2018, retrieved from the Hospital’s Electronic Medical Records (EMR). Their demographic profile, clinical correlates, radiological profile and diagnostic details were studied. Benign tumours, malignant pleural disease and sarcomatoid tumors were excluded from this study. Results: Adenocarcinoma (AC) was detected among 70.4% of patients, Squamous cell carcinoma (SCC) among 15.3% and Small cell lung cancer (SCLC) among 14.3% of lung cancer admissions. Male to female ratio was 2.95:1. It was found that the median age of lung cancer patients was 61 years. >60% of lung cancer patients were from the 51 - 70 year age-group. Across the three types of cancers among the patients in Stage 3B to 4 strata, >35% received palliative chemotherapy and >20% received palliative chemotherapy + radiation. Conclusion: In our study, AC is the most common histological subtype (>70%) of lung cancer. The outcome of lung cancer patients can be considerably impacted by addressing risk factors through preventive measures implemented in the community.
A Novel Peptide from T-Cell Leukemia Translocation-Associated Gene (TCTA) Protein Inhibits Proliferation of a Small-Cell Lung Carcinoma  [PDF]
Shigeru Kotake, Toru Yago, Manabu Kawamoto, Yuki Nanke
Journal of Cancer Therapy (JCT) , 2013, DOI: 10.4236/jct.2013.48A007
Abstract:

In 2009, we demonstrated that a peptide, which we named “Peptide A”, derived from the extracellular domain of T-cell leukemia translocation-associated gene (TCTA) protein, inhibited both RANKL-induced human osteoclastogenesis and pit formation of mature human osteoclasts. Here, we examined the effect of Peptide A on the cell proliferation of cell lines of small-cell lung carcinoma, breast cancer, and prostate cancer: RERF-LC-MA, MCF-7, and PC-3, respectively. Peptide A inhibited the proliferation of RERF-LC-MA, but not MCF-7 or PC-3. TCTA protein was immunohistologically detected in RERF-LC-MA and MCF-7. Thus, Peptide A may provide a novel strategy for the therapy of the patients with small-cell lung carcinoma, especially with bone metastasis. In addition, Peptide A may be useful for the treatment of various cancer patients with bone metastasis.

Three cases of combined small cell lung carcinoma with review of the literature
？rem Hicran ？ZBUDAK,Güzide Ay？e G？KHAN,Gülay ？ZB？L？M,？mer ？ZBUDAK
Türk Patoloji Dergisi , 2008,
Abstract: Combined small cell lung carcinoma is an uncommon entity and constitutes 1-3% of all cases with small cell lung carcinoma (SCLC). We reported three cases of combined small cell lung carcinoma. All the cases were male (ages: 77, 60 and 55 years, respectively) with a history of heavy smoking and presented with lung masses. Additionally, first case had been a history of asbestos exposure for 5-6 years. Histopathological examination of biopsy specimens revealed a rare variant of small cell lung carcinoma ie combined small cell lung carcinoma. In addition to histological evidence of small cell lung carcinoma, the first biopsy specimen also contained areas of squamous cell carcinoma and the other two biopsy specimens revealed adenocarcinomatous cells. Immunohistochemical findings supported the diagnosis. Combined small cell lung carcinoma is very rare, but is nevertheless a well described diagnostic category among lung cancers. In this case report, because of the rarity of these tumors, we discussed combined small cell lung carcinoma in view of the literature.
Cytokeratin-negative small cell lung carcinoma
Tadashi Terada
Rare Tumors , 2011, DOI: 10.4081/rt.2011.e38
Abstract: Cytokeratins (CK) are good markers of epithelial tumors, and most of carcinomas including small cell lung carcinoma (SCLC) expresses CK. Herein reported is a case of SCLC without CK expression.
Small-cell Lung Cancer Presenting as Fatal Pulmonary Hemorrhage
Hae-Seong Nam,Hong Lyeol Lee,Hyun-Jung Kim,Jae Hwa Cho,Jeong-Seon Ryu,Jun Hyeok Lim,Jung Soo Kim,Sang Hoon Jeon,Sang Yong Cho,Seung Min Kwak
- , 2018, DOI: 10.1515/med-2018-0009
Abstract: Small-cell lung cancer (SCLC) is a lung cancer histological subtype unusual in its favorable response to cytotoxic chemotherapy. Life-threatening manifestations at presentation are rarely reported and should be an important clinical concern. We report a case of a 63-year-old man presenting with rapid-onset refractory severe thrombocytopenia, development of massive hemoptysis, and death from respiratory failure. This case provides clinicians a reference for this unusual presentation and carries clinical implications for managing SCLC patients
Clinical Analysis of 58 Patients with Small Cell Lung Cancer ？Combined with Squamous Cell Cancer
Yang LUO, Yu MEN, Zhouguang HUI, Junling LI, Xuezhi HAO, Puyuan XING
- , 2016, DOI: : 10.3779/j.issn.1009-3419.2016.10.04
Abstract: Background and objective Small cell lung cancer combined with squamous cell carcinoma are rare. The aim of this study was to analyze the clinicopathological characteristics and treatment, and explored the prognostic factors of this disease. Methods Between January 2004 and December 2012, 58 patients with cytopathologically confirmed small cell lung cancers combined with squamous cell carcinoma were retrospectively analyzed. Kaplan-Meier methods were used to calculate the survival rate, and Log-rank test was used to examine differences between arms. The Cox regression model was used to analyze the independent factors affecting the overall survival (OS). Results The OS of the 58 patients was 22.7 months with a range of 0.3 to 124.3 months. In univariate analysis, Karnofsky performance score before treatment, extensive disease, tumor stage were the considered prognostic factors affecting the OS rate (P<0.05). Cox multivariate analysis showed that only the tumor-node-metastasis (TNM) stage was the independent prognostic factor (P=0.019). The majority of the patients received multimodality therapy and chemotherapy was the main treatment. Distant metastasis was the main reasonfor the treatment failure. Conclusion Combined therapy with chemotherapy as the main treatment should be adopted in therapeutic regimen of the patients with small cell lung cancers combined with squamous cell carcinoma. TNM stage was the independent prognostic factor influencing the OS.
Trinta anos de irradia？？o craniana profilática em pacientes com cancer de pulm？o de pequenas células: uma meta-análise de ensaios clínicos randomizados
Viani, Gustavo Arruda;Boin, André Campiolo;Ikeda, Veridiana Yuri;Vianna, Bruno Silveira;Silva, Rondinelli Salvador;Santanella, Fernando;
Jornal Brasileiro de Pneumologia , 2012, DOI: 10.1590/S1806-37132012000300013
Abstract: objective: to determine the role of prophylactic cranial irradiation (pci) in patients with small cell lung cancer (sclc). methods: we searched various databases, selecting randomized clinical trials published in journals or conference proceedings within the last 30 years and investigating the role of pci in the mortality of patients with sclc, submitted to pci or not. results: sixteen randomized clinical trials, collectively involving 1,983 patients, were considered eligible for inclusion. of those 1,983 patients, 1,021 were submitted to pci and 962 were not. overall mortality was 4.4% lower in the patients submitted to pci than in those who were not (or = 0.73; 95% ci: 0.57-0.97; p = 0.01), especially among the patients showing a complete response after induction chemotherapy (or = 0.68; 95% ci: 0.50-0.93; p = 0.02) and in those submitted to pci after that treatment (or = 0.68; 95% ci: 0.49-0.94; p = 0.03). that decrease did not correlate with the stage of the disease: limited disease (or = 0.73; 95% ci: 0.55-0.97; p = 0.03); and extensive disease (or = 0.48; 95% ci: 0.26-0.87; p = 0.02). conclusions: our findings suggest that pci decreases mortality in patients with sclc, especially in those showing a complete response after induction chemotherapy and in those submitted to pci after that treatment, regardless of the stage of the disease.
Small Cell Anaplastic Carcinoma of Primary Lung Tumor in a Miniature Schnauzer Dog
J. M. Kim, H. J. Han, B. Ku, G. Kim, K. M. Shim1, S. S. Kang2 and S. H. Choi*
Pakistan Veterinary Journal , 2011,
Abstract: A seven-year-old male, an intact miniature Schnauzer dog with history of vomiting, abdominal distention, anorexia, and dyspnea was referred for further evaluation and treatment. Thoracic radiographs showed the well marginated solitary mass with soft density in the right caudal lung field, and abdominal radiographs showed signs of ascites, such as abdominal distention and moderate serosal detail loss. On ultrasonograph and computed tomograph, it was observed that the mass compressed the caudal vena cava (CVC) and adhered to the heart. Exploratory thoracotomy was performed, and then it was showed that mass adhered heart, CVC, and diaphragm. The mass was fully resected although adhered part of CVC could not be completely resected. On histopathological findings, the mass was diagnosed as small-cell anaplastic carcinoma.
Paclitaxel and Carboplatin in Elderly Pat ents with Advanced Non-small Cell Lung Cancer
？zkan Kanat,Erdem ？ubukcu,Sinem ？ubukcu,Mustafa Canhoroz
Journal of Clinical and Analytical Medicine , 2012, DOI: 10.4328
Abstract: Aim: In this study, the safety and tolerability of paclitaxel and carboplatin (PC) regimen in elderly patients with advanced non-small cell lung cancer (NSCLC) was investigated. Material and Method: Elderly patients (ages ≥70 years) who received PC for stage III (n=11) or IV (n=34) NSCLC were evaluated retrospectively. Results: There were 43 males and 2 females, with a median age of 75.5 (range, 70-82). The response rate was 40%. The median overall survival time and progression-free survival time was 13 months and 8.5 months, respectively. One-year survival rate was 51%. Treatment was well tolerated by the patients. The most frequent side effect observed was grade 3 or 4 neutropenia (57.7%). There was no treatment-related death. Discussion: PC regimen may be a good alternative for the treatment of elderly patients with advanced NSCLC.
Subcuteneous swelling as the first clinical manifestation of small cell carcinoma of lung
Sunil Kumar,Amit Gupta,Sanjay K. Diwan,Arvind Bhake
Clinics and Practice , 2012, DOI: 10.4081/cp.2012.e62
Abstract: Subcutaneous swelling as first clinical presentation of small cell lung carcinoma is uncommon and rarely reported in literature. This case highlights a rare presentation in which subcutaneous swelling was the first clinical manifestation of a small cell carcinoma of lung which also had metastasis to rib bone, muscle and pleural involvement as pleural effusion. We describe the case of a 64-year-old male patient who presented with dyspnea, pleuritic pain, loss of weight and nodule on his anterior chest, back and left arm suspicious of lipoma. Biopsies revealed small cell carcinoma of lung. This case demonstrates the meticulous work up of subcutaneous swelling in the clinical scenario of breathlessness, chest pain and loss of weight.
第1页/共1000条
每页显示 条


Home
Copyright © 2008-2020 Open Access Library. All rights reserved.